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Summary
Objective To document utilization of lipid-lowering
therapy, attainment of low-density lipoprotein cholesterol target values, and cardiovascular outcomes in
patients hospitalized for acute coronary syndrome in
Germany.
Methods The Dyslipidemia International Study II was
a multicenter, observational study of the prevalence
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of dyslipidemia and lipid target value attainment
in patients surviving any acute coronary syndrome
event. Among patients on lipid-lowering therapy
for ≥3 months, use of lipid-lowering therapy and
lipid profiles were assessed at admission and again
at 120 ± 15 days after admission (the follow-up time
point). Multivariate logistic regression was used to
identify variables predictive of low-density lipoprotein cholesterol target value attainment in patients
using lipid-lowering therapy.
Results A total of 461 patients hospitalized for acute
coronary syndrome were identified, 270 (58.6%) of
whom were on lipid-lowering therapy at admission.
Among patients on lipid-lowering therapy, 90.7% and
85.9% were receiving statin monotherapy at admission and follow-up, respectively. Mean (SD) lowdensity lipoprotein cholesterol levels in patients on
lipid-lowering therapy were 101 (40) mg/dl and 95
(30) mg/dl at admission and follow-up, respectively.
In patients with data at both admission and followup (n = 61), low-density lipoprotein cholesterol target value attainment rates were the same (19.7%)
at both time points. Smoking was associated with
a 77% lower likelihood of attaining the low-density
lipoprotein cholesterol target value.
Conclusion Hospitalization for an acute event does
not greatly alter lipid management in acute coronary
syndrome patients in Germany. Both lipid-lowering
therapy doses and rates of low-density lipoprotein
cholesterol target value attainment remained essentially the same several months after the event.
Keywords Acute coronary syndrome · Myocardial infarction · Dyslipidemias · Cholesterol · LDL
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Introduction
Acute coronary syndrome (ACS) is a serious and lifethreatening clinical manifestation of atherosclerosis.
It is characterized by a thromboembolic event leading to a sudden reduction in blood flow to the heart
[1]. An ACS presents as one of several sub-types,
including ST segment elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction
(NSTEMI), and unstable angina. European Society of
Cardiology (ESC) guidelines for the management of
ACS acknowledge that secondary prevention of cardiovascular events requires treatment of dyslipidemia,
if present [1, 2]. Specifically, long-term treatment of
low-density lipoprotein cholesterol (LDL-C) serum
levels to a target value of <70 mg/dl (1.8 mmol/l) is
recommended, with high-dose statins and ezetimibe
as the preferred lipid-lowering therapy (LLT; [2, 3]).
These targets have been confirmed by the guidelines
for the management of dyslipidemia published by the
European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) task force in 2011
[4].
Germany has made several improvements in the
management of cardiovascular disease risk factors in
ACS patients. Rates of treatment of dyslipidemia in
patients with a history of ACS increased from 35%
to 87% between 1995 and 2007 [5], and nationwide
implementation of smoking restrictions in 2007–2008
was followed by 13.3% and 8.1% declines, respectively, in the annual rates of hospitalization for angina
pectoris and myocardial infarction (MI; [6]); however,
rates of hospitalization for MI in Germany remain
well above the median for European countries [7]. An
analysis of the German 2L registry of patients with
coronary heart disease (CHD) showed that most patients treated for dyslipidemia received low-intensity
statin regimens [8]. Not surprisingly, the Dyslipidemia
International Study (DYSIS) found that, among statintreated patients in Germany, 58.1% failed to attain the
LDL-C target value for high risk patients (<100 mg/dl;
2.6 mmol/l) [9], and a large German population-based
cross-sectional study found that among statin-treated
CHD patients, the estimated 10-year risk of a coronary event was 35.1%, well above the threshold for
LLT [10].
Given the state of cardiovascular management in
Germany and the current guidelines for treatment of
ACS, the primary objective of the second DYSIS (DYSIS II) was to document utilization of LLT, LDL-C target value attainment, and cardiovascular health outcomes in patients hospitalized for ACS in Germany.

Patients, materials and methods
Study design
The DYSIS II is an international, multicenter, observational study being conducted throughout Europe,
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Asia, and the Middle East to determine the prevalence of dyslipidemias and lipid target value attainment in patients with stable CHD and in patients hospitalized for an ACS event. The ACS cohorts were assessed longitudinally as described later. All data were
collected via a web-based data collection form using
software developed by the Institute for Heart Infarction Research (Institut für Herzinfarktforschung, IHF)
in Ludwigshafen, Germany.
In the German ACS cohort, 21 sites participated
in data collection from consecutive patients. Acute
care centers were selected to be representative of the
acute and ambulatory treatment of secondary prevention in Germany. The patient recruitment period was
May 2013 to July 2014. Data were collected by clinical
examination and from medical charts at admission
to the hospital, and again via a telephone interview
at 120 ± 15 days after admission (the follow-up time
point). At the time of enrolment, patients were given
a booklet and instructed to take it with them when
they next visited their physician post-discharge (from
current hospitalization). The booklet was filled out
during the follow-up office visit by the physician and
registered the patient’s lipid profile and other basic
patient characteristics. The information in the booklet was to be used by the patient during the follow-up
telephone interview. The protocol was approved by
local and regional institutional review boards as per
local regulations.

Study sample
Patients included in the current analysis were ≥18 years
of age, had been hospitalized for ACS in Germany, and
had a full lipid profile based on blood drawn within
24 h of admission. Patients must have been on LLT
for ≥3 months, or not taking LLT at all, at the time
of admission to the hospital. Patients taking LLT for
<3 months were excluded from the analysis. Each
patient provided written informed consent specifying
non-participation in any randomized clinical trials
and would not do so for the duration of the study.

Study definitions and outcome variables
In this study, ACS was defined as one or more of the
following events: STEMI/left bundle branch block
(LBBB), NSTEMI, or unstable angina. Demographic
and clinical characteristics collected at admission
included age, gender, body mass index, sedentary
life style, smoking status, and family history of CHD.
Comorbidities (e. g., hypertension, type 2 diabetes
mellitus) and cardiovascular history (of CHD, MI,
chronic renal failure, chronic kidney disease, stroke,
or peripheral vascular disease) were also recorded.
Obesity was defined according to the World Health
Organization (WHO) criteria as having a body mass
index >30 kg/m2. Hypertension was defined as current antihypertensive treatment, a previous diagnosis,
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or having blood pressure >140/90 mm Hg. Similarly,
diabetes was defined as current treatment for diabetes, a previous diagnosis of diabetes, or a fasting
plasma glucose level of ≥126 mg/dl. A sedentary
life style was defined as <20–30 min of walking on
<3–4 days per week. Stroke was either ischemic or
hemorrhagic. Use of selected classes of cardiovascular medications (e. g., beta-blockers, calcium channel
blockers, diuretics, angiotensin-converting enzyme
(ACE) inhibitors, antiplatelet agents) and laboratory
values of hemoglobin A1c and serum glucose were
also recorded at admission.
Patients were divided into two subgroups, treated
or untreated, based on their lipid treatment status
at admission, as defined above. Use of LLTs at the
time of the lipid test was determined by chart review at admission and by patient report at follow-up.
The following mutually exclusive classes of LLT were
assessed: statin monotherapy, non-statin monotherapy, statin plus ezetimibe, and statin plus other nonstatin therapy (“other” non-statins included fibrates
and omega-3 fatty acids). The statins assessed were
simvastatin, atorvastatin, rosuvastatin, pravastatin,
lovastatin, and fluvastatin. Atorvastatin and simvastatin dose equivalents were calculated based on
clinical trial data on the LDL-C-lowering efficacy of
various statins [11]. Attainment of lipid target values
was assessed among treated patients at admission and
follow-up, using lipid values determined within 24 h
of admission and lipid values determined between
admission and the follow-up interview, respectively.
The lipid profile included measurement or calculation of serum levels of total cholesterol, LDL-C, highdensity lipoprotein cholesterol (HDL-C), triglycerides,
and non-HDL-C. The LDL-C target values were assigned according to the patient’s cardiovascular risk,
which was determined using two methods. First, preACS risk status (i.e. very high, high, moderate or low)
was determined for all patients based on selected
patient characteristics, and second, all patients were
classified as being at very high risk because of the
ACS event leading to hospitalization. Target values

for LDL-C for very high risk, high risk, moderate risk,
and low risk patients were defined according to the
2011 ESC/EAS guidelines as <70 mg/dl, <100 mg/dl,
<115 mg/dl, and <130 mg/dl, respectively [4]. Per the
same guidelines, the non-HDL-C target value was
<100 mg/dl [4]. The median distance to the LDLC target value was calculated for patients who had
not attained the LDL-C target value on the date of
the lipid profile. Attainment of the secondary nonHDL-C target value (<100 mg/dl) was also assessed at
admission and follow-up. Cardiovascular health outcomes assessed at follow-up were rehospitalization,
MI, stroke, percutaneous coronary intervention, and
coronary artery bypass graft.

Statistical analysis
This study analyzed the ACS patients on LLT at admission through the follow-up time point. Unless
otherwise specified, the designations of “treated” or
“on LLT” refer to the treatment status at admission,
regardless of the treatment status at follow-up. Demographic and clinical characteristics, use of cardiovascular medications, and cardiovascular outcomes were
compared between patients on LLT and not on LLT at
admission using χ2 or Mann-Whitney-Wilcoxon tests.
Lipid profiles, LDL-C target value attainment, and
types of LLT used at admission and follow-up were
assessed descriptively in patients on LLT. In all univariate analyses, continuous variables are presented
as means and standard deviations (SDs) or medians
and interquartile ranges (IQRs), and categorical variables are presented as numbers and/or percentages.
Multivariate logistic regression was used to identify
variables predictive of LDL-C target value attainment
in patients on LLT at admission. Covariates, including
age, gender, obesity, current smoking, sedentary life
style, stable angina, chronic kidney disease, type 2
diabetes mellitus, history of congestive heart failure,
hypertension and statin dose (i. e., atorvastatin dose
equivalent), were chosen based on their potential to
affect LDL-C target value attainment, and no statistical selection methods were applied. Assessment of
cardiovascular outcomes at follow-up was done using
Kaplan-Meier analysis, with P values calculated by
a log-rank test. SAS version 9.3 (Cary, NC, USA) was
used for all calculations. In all analyses, a P value
<0.05 was considered statistically significant.

Results
Characteristics of the study population

Fig. 1 Flowchart for patients in the study. ACS acute coronary syndrome, LLT lipid-lowering therapy, LDL-C low-density
lipoprotein cholesterol
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The study identified 461 patients hospitalized for ACS
in Germany in 2013–2014 (Fig. 1). The mean (SD)
age of the study population was 64.1 (11.7) years, and
75.5% were male (Table 1). More than half of the patients had hypertension (80.9%) or documented CHD
(56.9%). The most frequently used types of cardiovas-
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Table 1

Demographic and clinical characteristics of the study populationa
All patients (N = 461)

Patients on LLT
(N = 270)

Patients not on LLT
(N = 191)

P valueb

Age, mean (SD) years

64.1 (11.7)

66.4 (10.5)

60.8 (12.6)

<0.001

Male

348 (75.5)

212 (78.5)

136 (71.2)

0.07

Obesec

149 (32.4)

100 (37.2)

49 (25.7)

<0.01

Hypertension

373 (80.9)

244 (90.4)

129 (67.5)

<0.001

Type 2 diabetes mellitusc

133 (29.0)

102 (37.9)

31 (16.3)

<0.001

Oral medication for control of diabetes

72 (15.6)

57 (21.1)

15 (7.9)

0.54

Sedentary life stylec

94 (24.5)

49 (21.6)

45 (28.7)

0.11

Current smoker

126 (27.3)

58 (21.5)

68 (35.6)

<0.001

Documented CHDc

256 (56.9)

214 (80.8)

42 (22.7)

<0.001

History of MIc

133 (30.1)

122 (47.7)

11 (5.9)

<0.001

History of CRF/CKD

54 (11.7)

44 (16.3)

10 (5.2)

<0.001

Family history of CHDc

191 (48.0)

124 (54.9)

67 (39.0)

<0.01

History of stroke (ischemic or hemorrhagic)

26 (5.9)

21 (8.1)

5 (2.7)

<0.05

History of peripheral vascular diseasec

39 (8.6)

32 (12.0)

7 (3.7)

<0.01

STEMI/LBBB MI

142 (30.8)

54 (20.0)

88 (46.1)

<0.001

NSTEMI

187 (40.6)

119 (44.1)

68 (35.6)

0.07

Unstable angina

132 (28.6)

97 (35.9)

35 (18.3)

<0.001

Beta-blockers

286 (63.1)

220 (81.8)

66 (35.9)

<0.001

Calcium channel blockers

79 (17.6)

60 (22.5)

19 (10.4)

<0.001

Diuretics

121 (26.7)

93 (34.6)

28 (15.2)

<0.001

ACE inhibitors

210 (46.4)

162 (60.2)

48 (26.1)

<0.001

Angiotensin receptor blockers

77 (17.1)

51 (19.2)

26 (14.1)

0.16

Acetylsalicylic acid

262 (57.8)

212 (78.5)

50 (27.3)

<0.001

Other antiplatelets

90 (19.5)

73 (27.0)

17 (8.9)

<0.001

Clopidogrel

49 (10.6)

38 (14.1)

11 (5.8)

0.35

Prasugrel

16 (3.5)

15 (5.6)

1 (0.5)

0.15

Ticagrelor

23 (5.0)

18 (6.7)

5 (2.6)

0.69

Other

2 (0.4)

2 (0.7)

0 (0.0)

0.49

Hemoglobin A1c, mean (SD) %

6.4 ± 1.5

6.7 ± 1.4

6.1 ± 1.6

<0.01

Serum glucose, mean (SD) mg/dl

131.8 ± 46.4

133.6 ± 50.2

129.5 ± 40.9

0.96

c

Type of ACS at admission

Medication use

c

Laboratory values

ACS acute coronary syndrome, ACE angiotensin-converting enzyme, CHD coronary heart disease, CKD chronic kidney disease, CRF chronic renal failure,
LBBB left bundle branch block, LLT lipid-lowering therapy, MI myocardial infarction, NSTEMI non-ST elevation myocardial infarction, SD standard deviation,
STEMI ST segment elevation myocardial infarction
a
Data are presented as numbers and percentages unless otherwise indicated
b
P values reflect χ2 or Mann-Whitney-Wilcoxon tests between values for treated and untreated patients
c
Values were calculated based on the number of patients with available data rather than the total study or subgroup population

cular medication were beta blockers (63.1%), acetylsalicylic acid (57.8%), and ACE inhibitors (46.4%).
Mean (SD) values of hemoglobin A1c and serum
glucose were 6.4% (1.5%) and 131.8 (46.4) mg/dl,
respectively. During the hospital stay, 388 patients
(84.2%) underwent echocardiography, 310 (67.2%) received a percutaneous coronary intervention, and 194
(42.1%) underwent coronary angiography (data not
shown).
A total of 270 patients (58.6%) were on LLT at admission and 191 were not (Fig. 1; Table 1). Patients not
on LLT at hospital admission were younger compared
to those on LLT (60.8 versus 66.4 years, P < 0.001) and
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had significantly lower rates of obesity (25.7% versus
37.2%, P < 0.01), hypertension (67.5% versus 90.4%,
P < 0.001), diabetes (16.3% versus 37.9%, P < 0.001),
documented CHD (22.7% versus 80.8%, P < 0.001),
and history of MI (5.9% versus 47.7%, P < 0.001). The
use of almost all types of cardiovascular medications
was significantly less frequent in patients not on LLT
than those on LLT (Table 1), and patients not on LLT
were more frequently current smokers (35.6% versus 21.5%, P < 0.001) and more often presented with
STEMI/LBBB MI (46.1% versus 20.0%, P < 0.001).
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Table 2
Lipid-lowering
therapy at discharge and
follow-up

Discharge
(N = 270)

Follow-upa
(N = 242)

Statins, n (%)

264 (97.8)

209 (86.4)

Atorvastatin, n (%)

59 (21.9)

52 (21.5)

Mean (SD) dose, mg/day

37 ± 14

38 ± 16

Fluvastatin, n (%)

8 (3.0)

7 (2.9)

Mean (SD) dose, mg/day

48 ± 21

51 ± 20

Lovastatin, n (%)

0 (0.0)

0 (0.0)

Mean (SD) dose, mg/day

–

–

Pravastatin, n (%)

10 (3.7)

12 (5.0)

Mean (SD) dose, mg/day

32 ± 13

31 ± 12

Rosuvastatin, n (%)

0 (0.0)

0

Mean (SD) dose, mg/day

–

–

Simvastatin, n (%)

187 (69.3)

134 (55.4)

Mean (SD) dose, mg/day

34 ± 12

33 ± 12

Pitavastatin, n (%)

0 (0.0)

0

Mean (SD) dose, mg/day

–

–

Non-statins, n (%)

22 (8.1)

22 (9.1)

Ezetimibe, n (%)

19 (7.0)

18 (7.4)

Fibrates, n (%)

2 (0.7)

3 (1.2)

Nicotinic acids, n (%)

0 (0.0)

0 (0.0)

Laropiprant, n (%)

0 (0.0)

0 (0.0)

Omega-3 fatty acids, n (%)

1 (0.4)

0 (0.0)

a

Although 242 patients were included in the follow-up analyses, only 65, 61, 62, 56, and 57 patients had lipid profile
data for total cholesterol, LDL-C, HDL-C, triglycerides, and non-HDL-C, respectively, at follow-up

Table 3 Lipid profiles, distance to target, and dose
equivalents among treated
patients at admission and
follow-up

Admission
(N = 270)

Follow-upa
(N = 242)

Total cholesterol, mean (SD)

174 (50)

165 (32)

LDL-C, mean (SD)

101 (40)

95 (30)

HDL-C, median (IQR)

43 (36, 50)

50 (40, 59)

Triglycerides, median (IQR)

122 (85, 185)

128 (95, 164)

Non-HDL-C, median (IQR)

121 (98, 152)

115 (98, 143)

Distance to LDL-C <70 mg/dl, median (IQR)b

34 (17, 60)

31 (11, 55)

Atorvastatin dose equivalent, mean ± SD mg/dayc

18 ± 12

22 ± 15

Lipid concentrations, mg/dl

HDL-C high-density lipoprotein cholesterol, IQR interquartile range, LDL-C low-density lipoprotein cholesterol, SD standard deviation
a
Although 242 patients were included in the follow-up analyses, only 65, 61, 62, 56, and 57 patients had lipid profile
data for total cholesterol, LDL-C, HDL-C, triglycerides, and non-HDL-C, respectively, at follow-up
b
Among patients not yet attaining the target level
c
For comparison, the simvastatin dose equivalents were 37 ± 23 mg/day at admission and 44 ± 31 mg/day at follow-up

Use of lipid-lowering therapies
Among the 270 treated patients, 97.8% were receiving statins at admission (Table 2), and the most commonly used statins were simvastatin (69.3%) and atorvastatin (21.9%; Table 2). In addition, 8.1% of patients
were taking non-statin LLT. At admission, the mean
(SD) atorvastatin dose equivalent was 18 (12) mg/day
(Table 3). At the time of the follow-up interview, only
86.4% of patients on LLT at admission reported taking
statins (Table 2). Simvastatin use decreased to 55.4%
at follow-up, and atorvastatin held steady at 21.5%

K

(Table 2). The mean (SD) atorvastatin dose was 22
(15) mg/day (Table 3).

Lipid profiles and lipid target value attainment
At admission, mean (SD) total cholesterol and LDLC levels in patients on LLT were 174 (50) mg/dl and
101 (40) mg/dl, respectively (Table 3). Median (IQR)
HDL-C, triglyceride, and non-HDL-C levels were 43
(36–50) mg/dl, 122 (85–185) mg/dl, and 121 (98–152)
mg/dl, respectively. Among the 242 patients with follow-up data, values for total cholesterol, LDL-C, and
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Fig. 2 LDL-C target value
attainment, by a pre-ACS
risk level and b time point.
a Risk levels were determined using chart data from
the pre-ACS period. LDLC targets were as follows:
very high risk, <70 mg/dl;
high risk, <100 mg/dl; moderate risk, <115 mg/dl; and
low risk, <130 mg/dl. b Goal
attainment is shown in a kernel density plot for the subgroup of 61 treated patients
for whom LDL-C data were
available at both admission (blue line) and followup (green line). The X-axis
shows LDL-C levels and the
Y-axis shows the percentage of patients. Follow-up
data were collected 120
days after admission to
the hospital. LDL-C lowdensity lipoprotein cholesterol

non-HDL-C decreased at follow-up, while the levels of
HDL-C and triglycerides increased (Table 3).
At admission, 27.8% of treated patients had attained the non-HDL-C target, and 31.6% had done so
by the follow-up assessment (data not shown). Among
treated patients with very high pre-ACS risk (N = 203),
only 24.6% attained LDL-C target values at admission
(Fig. 2a). The LDL-C target value attainment rates
for patients classified pre-ACS as high, moderate, and
low risk were 37.5%, 62.1%, and 80.0%, respectively
(Fig. 2a).
When all patients on LLT (N = 270) were classified as
very high risk because of their hospitalization for ACS,
21.9% had attained the LDL-C target value at admission (data not shown). Among those not attaining the
LDL-C target, the median (IQR) distance to the target
value at admission was 34 (17–60) mg/dl (Table 3). At
the time of follow-up, 61 treated patients had data for
LDL-C at both admission and follow-up, and 19.7% of
them had attained the LDL-C target value (Fig. 2b).
Among these 61 patients, target value attainment at
admission was 19.7% (Fig. 2b). Among treated patients not attaining the LDL-C target value at followup, the median (IQR) distance to the target was 31
(11–55) mg/dl (Table 3).
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In multivariate regression analyses of LDL-C target value attainment (Table 4), chronic kidney disease
was associated with 3-fold higher odds of attainment
(odds ratio OR 3.12, 95% CI 1.29–7.55), while current
smoking was associated with a 77% lower likelihood
of attaining the LDL-C target value (OR 0.23, 95% CI
0.07–0.72).

Discussion
The DYSIS II assessed lipid profiles and LDL-C target
value attainment longitudinally in patients receiving
LLT who were hospitalized for ACS in Germany. Approximately 20% of treated German ACS patients with
data at both admission and follow-up attained the
recommended LDL-C level of <70 mg/dl, with no apparent gains between hospitalization and follow-up.
Over the same time interval, triglyceride levels actually increased. These findings suggest potential reasons for such poor outcomes: LLT at admission consisted mainly of statin monotherapy (primarily simvastatin), and the mean atorvastatin dose equivalent
increased only slightly, from 18 to 22 mg/day, between
admission and follow-up.
According to the 2011 ESC/EAS guidelines [4] and
the more recently published 2016 ESC/EAS guidelines
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Table 4 Predictors of LDLC target value attainment in
patients on LLT at admissiona

Odds ratio

95% CI

P-value

Age ≥70 years

0.71

0.33–1.52

0.376

Female

1.39

0.59–3.32

0.454

BMI >30 kg/m2

0.98

0.44–2.17

0.960

Current smoking

0.23

0.07–0.72

0.012

Sedentary life style

0.70

0.29–1.69

0.426

Chronic kidney disease

3.12

1.29–7.55

0.012

Type 2 diabetes mellitus

1.18

0.54–2.59

0.680

History of congestive heart failure

1.16

0.34–3.96

0.819

Hypertension

0.51

0.17–1.55

0.235

Statin dose (atorvastatin dose equivalent, mg/day)

1.02

0.988–1.05

0.220

BMI body mass index, CI confidence interval
a
Bold print indicates statistical significance

[12], all patients experiencing an ACS event should
receive pharmacologic treatment. The EUROASPIRE
surveys I–III showed that between 1995 and 2007 rates
of treatment for lipid abnormalities among German
patients with coronary events increased from 35.0%
to 87.0% (P < 0.001) [5]. Other studies of German patients hospitalized for an ACS event (STEMI, NSTEMI,
or unstable angina) reported statin treatment rates at
discharge ranging from 73% to 94.6% [13–16]; however, EUROASPIRE IV found that in Germany low/
moderate-intensity LLTs are much more frequently
used than high-intensity LLTs [17], consistent with our
finding that simvastatin was the most commonly used
LLT in DYSIS II. Other studies have found that simvastatin is the most commonly prescribed statin in
Germany [8–10] and that non-statins are used infrequently for lipid control [8, 9]. The 2016 ESC/EAS
guidelines state that lipid values should be re-evaluated 4–6 weeks after ACS to determine whether lipid
goals have been reached and if the therapeutic regimen needs to be adapted [12]. In this study only
a slight increase in dose strength was noted, from
18 to 22 mg/day, between admission and follow-up
(120 ± 15 days after admission). Very often statin treatment initiated during the hospital stay is done so with
low dosages and is expected to be up-titrated during
follow-up. Our data indicate that this up-titration is
not taking place. Use of less effective LLTs and failure
to increase the dose potency after a coronary event
may explain the low attainment of the LDL-C target
value in German ACS patients.
As has been elucidated in the past [8], office-based
physicians in Germany will likely not intensify LLT
in most cases after discharge from hospital. It is
therefore proposed to discharge patients post-ACS
with high intensity LLT, including a potent statin and
ezetimibe. The newly available PCSK9 inhibitors are
an additional option to treat ACS patients, but the
use of this therapy is limited in Germany. Before
using a PCSK9 inhibitor, all other available therapeutic options must be exhausted, e. g., use of a potent
statin (e. g., 40 mg atorvastatin) and the combination
with ezetimibe. Consistent use of this strategy would
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bring most patients to the treatment goal. Additionally, clear advice in the discharge letter concerning
the treatment goal and the therapeutic options could
help general practitioners in the clinical setting to
optimize the patients’ therapy. The ACS patients in
Germany should also be encouraged to take part in rehabilitation programs after an acute event to improve
the individual prognosis. In terms of identifying those
patients at highest risk, the validated TRS2P score
provides a modern and easy to use tool [18].
Among patients with data at both admission and
follow-up, the LDL-C target value attainment rate in
the German ACS cohort of DYSIS II did not change
from hospital admission to follow-up. In part because
previous studies of lipid target value attainment in
Germany have used different targets, the reported
rates of attainment are somewhat higher than in
DYSIS II. The DYSIS applied a target of <100 mg/dl
to high-risk statin-treated patients, and accordingly
41.9% of high-risk patients, as well as 47.3% of patients with cardiovascular disease, attained the target
value [9]. Other studies applying the <100 mg/dl target to statin-treated patients in Germany have found
LDL-C target value attainment rates of ~43–50% [8,
19]. Similarly, among German patients undergoing
inpatient cardiac rehabilitation after hospitalization
for an acute coronary event, 69.6% attained an LDLC level <100 mg/dl by the discharge date [14]. To our
knowledge, DYSIS II is the first study to assess attainment of the more stringent <70 mg/dl target value in
ACS patients in Germany.
The only variable positively associated with LDLC target value attainment in the current study was
chronic kidney disease, which was associated with
3-fold higher odds of attainment. According to the
2016 ESC/EAS guidelines, patients with chronic kidney disease are considered as high-risk or very highrisk patients and should be treated accordingly [12].
Because these patients are treated as high or very high
risk, regardless of LDL-C values, it is possible that the
more aggressive treatment protocol resulted in higher
odds of LDL-C attainment. Smoking, on the other
hand, was associated with a 77% lower likelihood of
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attaining the LDL-C target value. This result is consistent with the results from the German cohort of DYSIS,
which found smoking to be associated with higher
odds of LDL-C non-attainment in statin-treated patients [9].
One limitation of this study is that adherence to
treatment was not directly assessed. Although most
patients reported receiving a statin prescription at follow-up, actual medication-taking behavior was not
queried. Previous studies in Germany suggest that
adherence to statins falls by 20–35% within the first
year of use [13, 19, 20]. Secondly, a follow-up of
120 ± 15 days was too short to observe any changes in
therapy or cardiovascular outcomes. A long-term follow-up of the patients would be of interest to evaluate
any changes of therapy in the longer term of the disease. Per the findings of de Lemos et al. [21], the effect
of statin treatment on cardiovascular event risk reduction may not be evident until more time has passed.
Finally, data collection by telephone at follow-up may
not have been as accurate as the medical chart review
used for data collection at admission and may have affected the direction and degree of changes observed
over time.
In conclusion, this study of the German ACS cohort
of DYSIS II showed that LDL-C target value attainment
is suboptimal among very high-risk patients on LLT.
Hospitalization for an ACS event did not greatly alter
lipid management in ACS patients. Both LLT doses
and rates of LDL-C target value attainment remained
essentially the same several months after the event.
These results indicate that LLTs are not utilized in an
efficient manner in ACS patients in Germany, allowing cardiovascular mortality to remain high. An LLT
should be administered according to the latest guidelines, i. e., with higher doses and combination therapies, in order to help patients attain their LDL-C target
value and reduce their risk of cardiovascular events.
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